STOKE THERAPEUTICS, INC.
45 Wiggins Avenue
Bedford, MA 01730
July 16, 2020
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
|Office of Life Sciences|
|Re:||Stoke Therapeutics, Inc.|
|Registration Statement on Form S-3|
|Filed July 10, 2020|
|File No. 333-239801|
Via EDGAR - Acceleration Request
|Requested Date:||July 20, 2020|
|Requested Time:||4:00 p.m. Eastern Time|
Ladies and Gentlemen:
Stoke Therapeutics, Inc. (the Registrant) hereby requests that the Securities and Exchange Commission (the Commission) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the Requested Date and Requested Time set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Julia Forbess, both of whom are attorneys with the Registrants outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
|STOKE THERAPEUTICS, INC.|
|Robin A. Walker|
|Senior Vice President, Chief Legal|
Officer, Chief Compliance Officer and
|cc:||Edward M. Kaye, Chief Executive Officer|
|Stephen J. Tulipano, Chief Financial Officer|
|Stoke Therapeutics, Inc.|
|Robert A. Freedman, Esq.|
|Julia Forbess, Esq.|
|Fenwick & West LLP|